Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Date:2/6/2009

TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for patients diagnosed with schizophrenia or schizoaffective disorder.

Earlier this week, the company submitted its response to the FDA complete response letter for paliperidone palmitate, received in August 2008. Paliperidone palmitate is an investigational once-monthly atypical antipsychotic injection which, if approved, will be indicated for the acute and maintenance treatment of schizophrenia.

The company also submitted two supplemental new drug applications (sNDAs) to the FDA requesting approval for the use of INVEGA tablets for the treatment of schizoaffective disorder as monotherapy and for use in combination with antidepressants and/or mood stabilizers. The sNDA submissions include data from two international, 6-week double-blind placebo-controlled studies that evaluated the efficacy and safety of INVEGA in patients with schizoaffective disorder. If approved by the FDA, INVEGA would be the only medication indicated to treat the condition.

Patients with schizoaffective disorder experience the psychotic symptoms of schizophrenia, such as hallucinations or delusions, as well as mania and/or depression. Because of the similarity in symptoms, schizoaffective disorder is sometimes misdiagnosed as schizophrenia or bipolar disorder. For patients who frequently use mental health services, schizophrenia and schizoaffective disorder may account for approximately 32% and 24% of cases respectively.(i)

INVEGA, an atypical antipsychotic medication, was first approved in the U.S. in December 2006 and is marketed by Janssen. It is approved for the acute and maintenance treatment of schizophrenia in the U.S. an
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Blood Test for DepressionSAN DIEGO, April 23 ... commercializing its first-in-class, proprietary blood test for depression ... Phase 2, National Science Foundation, Small Business Innovation ... be used to further the clinical development and ...
... review of several vendors, the University of California ... services of Velos and its flagship product, Velos eResearch. ... UCLA,s Jonsson Comprehensive Cancer Center and an affiliated clinical ... in place to deploy the system in non-cancer studies ...
Cached Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... LOS ANGELES, Sept. 12 The Lupus Foundation,of America ... Jada Smith,Family Foundation is set to host the first ... at the historic El Rey Theatre in,Los Angeles on ... and funds for lupus. Butterflies Over Hollywood will ...
... TORONTO, Sept. 12 /PRNewswire-FirstCall/ - Transition Therapeutics ... a product-focused,biopharmaceutical company developing therapeutics for disease ... results for the year,ended June 30, 2007. ... fiscal 2007 and up to the date ...
... VivoMetrics(R) Inc. and the,Philadelphia Flyers of the ... incorporated the VivoChampionTrainer System into the team,s,training regimen ... use of,the VivoChampionTrainer as pre-season Training Camp kicked ... will be utilizing the VivoChampionTrainer to optimize their,players, ...
... Team Facilities Treated with the Antimicrobial Protection of the ... SportsAide(R) System from SportCoatings(TM), ... Nets are,the next team in the NBA scoring with ... from antimicrobial contamination. SportsAide is part of the ...
... Sept. 12 Children with asthma across the,country are ... annual "Living with Asthma" poster contest sponsored by the ... American Academy of,Pediatrics (AAP). More than 9 million children ... for them to understand that asthma shouldn,t,keep them from ...
... Meeting Expectations today announced,that it has been named ... the industry,s,largest and most influential full-service independent meeting ... market. Compiled by,Penton Media,s Corporate Meetings & Incentives(R) ... corporate meetings and events,industry, the CMI 25 provides ...
Cached Medicine News:Health News:The Will and Jada Smith Family Foundation and Maybelline Join Forces With the Lupus Foundation of America for a Star-studded Gala to Raise Awareness for Lupus 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 2Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 3Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 4Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 5Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 6Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 7Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 8Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 9Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 10Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 11Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 12Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 13Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 14Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 15Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 16Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 17Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 18Health News:Transition Therapeutics Announces Fiscal 2007 Year End Financial Results 19Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 2Health News:Philadelphia Flyers to Use VivoChampionTrainer(TM) System to Condition and Strengthen Players 3Health News:New Jersey Nets Shoot Down Staph with High-Tech Defense 2Health News:Kids, How Do You Manage Your Asthma? The AAAAI and AAP announce 17th annual poster contest 2Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: